DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges

Transl Lung Cancer Res. 2024 Mar 29;13(3):694-698. doi: 10.21037/tlcr-23-820. Epub 2024 Mar 20.

Authors

Rebecca Y Bellis¹, Prasad S Adusumilli^{1

2}, Alfredo Amador-Molina¹

Affiliations

¹ Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

No abstract available

Keywords: Small cell lung cancer (SCLC); chimeric antigen receptor T-cell (CAR T-cell); delta-like ligand 3 (DLL3); immunotherapy; lung cancer.

Publication types

Editorial
Comment